How can you tell? The relative silence in the mainstream media and on this floor from many of our Democratic colleagues tells you all you need to know.
We are concerned that Germany, Japan, and other high-income countries continue to maintain policies inconsistent with the Administration’s objective that U.S. trading partners pay their fair share for pharmaceutical innovation.